secwatch.observer — SEC 8-K summary
======================================

Issuer:     CARGO Therapeutics, Inc. (—)
CIK:        0001966494
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-059538
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CARGO Therapeutics reports Q1 2024 net loss $35.8M; Phase 2 firi-cel trial on track for 1H25 interim data
--------------------------------------------------------------------------------

- Q1 2024 net loss of $35.8M ($0.87/share); cash, equivalents and marketable securities $375.9M providing runway into 2026.
- Phase 2 FIRCE-1: 26 sites activated, >20 patients dosed; IDMC recommended continuation without modifications; interim results expected 1H25.
- Phase 1 Stanford firi-cel data: median OS 25.7 months at DL1; ORR 68%, CR 53% across all patients (n=38) at median follow-up 31.4 months.
- Dr. Kapil Dhingra appointed to board of directors in April 2024.
- R&D expenses $30.5M (incl. $1.7M stock-based comp); G&A expenses $10.3M (incl. $2.2M stock-based comp).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1966494/000095017024059538/0000950170-24-059538-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1966494/000095017024059538/crgx-20240514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-059538

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer